Vendor comparison · 2026
Selank vendors: 29 compared on COAs and price
OtherAlso known as TP-7
Evidence tier
Multiple human trials
3 human trials · 1 observational
- Vendors carrying it
- 29
- 26 with a listed price
- Vendors with checkable COAs
- 16
- 18 publish any certificate
- Lots tested
- 26
- 23 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- 23 Sept 2026
- oldest 1 May 2025
- Laboratories named
- 10
- most often Freedom Diagnostics Testing
- Median label gap
- 6.1%
- 42% of lots within 5% of label
- Median purity
- 99.57%
- 26 of 26 lots at 99% or above
- Lowest price per mg
- $1.90
- peer median $4.35
- Publications located
- 135
- researched since 2001
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
Featured in the October 2026 peptide COA report →
Next Gen Peptides has the most checkable Selank testing in this index: 5 lots assayed by ILS Laboratories, the newest on 23 Sept 2026. The lowest listed price is $1.90 per mg at Eternal Peptides, against a peer median of $4.35. 29 vendors carrying Selank are compared below. 16 publish at least one certificate naming a checkable laboratory, 26 lot records are on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying Selank
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Origin LabsISO/IEC 17025 | 96.9100% | $2.40 (55%) | 1 / 1 | Freedom Diagnostics Testing | 99.8% | 12.8% | ||
| 2 | Next Gen PeptidesISO/IEC 17025 | 92.897% | $3.00 (69%) | 5 / 5 | ILS Laboratories | 99.6% | 4.7% | ||
| 3 | Amino ClubISO/IEC 17025Age-gated COAs | 91.798% | $3.00 (69%) | 2 / 2 | ILS Laboratories | 99.5% | 6.3% | ||
| 4 | PeptidePlugs | 85.994% | $4.00 (92%) | 1 / 1 | Freedom Diagnostics Testing | 99.8% | 7.5% | ||
| 5 | One Aminos | 85.789% | $3.50 (81%) | 1 / 1 | United Laboratories | 99.5% | 15.0% | ||
| 6 | Bench Grade Peptides | 84.189% | $3.60 (83%) | 3 / 3 | Freedom Diagnostics Testing, AV Analytics | 99.7% | 9.5% | ||
| 7 | Ascend ScienceISO/IEC 17025 | 83.994% | $4.90 (113%) | 1 / 1 | Kovera Labs and/or ILS Labs | 99.8% | 20.0% | ||
| 8 | Hydro Research PeptidesISO/IEC 17025 | 83.989% | — | 0 / 1 | Not named | 99.0% | 44.6% | ||
| 9 | Stealth Research Labs | 83.791% | $4.00 (92%) | 1 / 1 | Bioviridian Inc. | 99.8% | 2.7% | ||
| 10 | NeuroLabs Research | 81.591% | $4.20 (97%) | 1 / 1 | Freedom Diagnostics Testing | 99.8% | 0.3% | ||
| 11 | Modern AminosISO/IEC 17025COAs need an account | 80.297% | $4.50 (103%) | 1 / 1 | Freedom Diagnostics Testing | 99.9% | 8.3% | ||
| 12 | Ascension Peptides | 78.489% | $5.00 (115%) | 1 / 1 | MZ Biolabs | 99.3% | 22.9% | ||
| 13 | Koi PeptidesAge-gated COAs | 7892% | $4.00 (92%) | 1 / 1 | Freedom Diagnostics Testing | 99.7% | 3.5% | ||
| 14 | CuroISO/IEC 17025 | 74.597% | $6.40 (147%) | 1 / 1 | BTLabs | 99.7% | 6.0% | ||
| 15 | Evo Labs Research | 73.987% | $4.00 (92%) | 0 | — | — | — | — | no reportVisit site |
| 16 | Simple Peptide | 73.892% | $5.50 (126%) | 1 / 1 | Freedom Diagnostics Testing | 99.3% | 20.3% | ||
| 17 | Northline LabsISO/IEC 17025 | 7195% | — | 1 / 1 | Horizon Analytical | 99.2% | 2.0% | ||
| 18 | GenX Peptides | 70.669% | $3.30 (76%) | 0 | — | — | — | — | no reportVisit site |
| 19 | Good Science Bio | 69.171% | $4.00 (92%) | 0 | — | — | — | — | no reportVisit site |
| 20 | Eternal Peptides | 6963% | $1.90 (44%) | 0 | — | — | — | — | no reportVisit site |
| 21 | Protide HealthAge-gated COAs | 68.292% | $6.50 (149%) | 0 | — | — | — | — | no reportVisit site |
| 22 | Licensed Peptides | 65.187% | $6.20 (143%) | 0 | — | — | — | — | no reportVisit site |
| 23 | True Research Labs | 61.568% | $4.90 (113%) | 0 | — | — | — | — | no reportVisit site |
| 24 | Improved Peptides | 61.487% | $5.60 (129%) | 0 | — | — | — | — | no reportVisit site |
| 25 | Biotech Peptides | 6160% | $4.60 (106%) | 0 | — | — | — | — | no reportVisit site |
| 26 | Vial Drop Labs | 59.474% | — | 1 / 1 | KMD Analytical (KMD Group LLC) | 99.9% | 0.0% | ||
| 27 | Evolve Peptides | 57.868% | $6.00 (138%) | 0 | — | — | — | — | no reportVisit site |
| 28 | BioLongevity Labs | 56.572% | $6.75 (155%) | 0 | — | — | — | — | no reportVisit site |
| 29 | Mile High Compounds | 50.691% | $6.50 (149%) | 0 / 2 | Not named | 99.0% | 1.5% |
Independent assays
No independently commissioned assay of Selank is on file. All 26 records below were published by the vendor that sells the product, naming the laboratory shown. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
What the certificates show
26 of 26 lots at 99% or above; median 99.57%.
| Range | lots |
|---|---|
| <95% | 0 |
| 95–97% | 0 |
| 97–98% | 0 |
| 98–99% | 0 |
| 99–99.5% | 10 |
| ≥99.5% | 16 |
42% of lots within 5% of the labelled mass; median gap 6.1%.
| Range | lots |
|---|---|
| ≤2% | 6 |
| 2–5% | 5 |
| 5–10% | 7 |
| 10–20% | 4 |
| >20% | 4 |
26 vendors, $1.90 to $6.75; median $4.35.
| Range | vendors |
|---|---|
| $1.00–$2.00 | 1 |
| $2.00–$3.00 | 1 |
| $3.00–$4.00 | 5 |
| $4.00–$5.00 | 10 |
| $5.00–$6.00 | 3 |
| $6.00–$7.00 | 6 |
Purity and mass are read from each certificate as published; the label gap is |labeled − assayed| ÷ labeled. Every value behind these bars is in the certificate table below.
Laboratories used
| Laboratory | Lots | Vendors | Share | Verify |
|---|---|---|---|---|
| Freedom Diagnostics TestingUS | 8 | 7 | 31% | Public lookup |
| ILS LaboratoriesUS | 7 | 2 | 27% | Public lookup |
| AV Analytics | 1 | 1 | 4% | No public lookup found |
| Bioviridian Inc.US | 1 | 1 | 4% | Public lookup |
| BTLabs | 1 | 1 | 4% | No public lookup found |
| Horizon Analytical | 1 | 1 | 4% | No public lookup found |
| KMD Analytical (KMD Group LLC)US | 1 | 1 | 4% | Public lookup |
| Kovera Labs and/or ILS Labs | 1 | 1 | 4% | No public lookup found |
| MZ BiolabsUS | 1 | 1 | 4% | No public lookup found |
| United LaboratoriesIN | 1 | 1 | 4% | Public lookup |
3 further records nameno checkable laboratory (a placeholder, a signature line or the vendor’s own name). They are listed in the certificate table but not counted as third-party testing.
Every certificate record
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2001 — 25 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
135 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.6% across 26 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.26 pts purity across lots, mean label deviation 9.0%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
29 of 29 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
23 of 26 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is Selank?
A synthetic heptapeptide based on the immune peptide tuftsin, studied in relation to anxiety and cognition. It was developed in Russia.
Studied in published research for anxiety, stress and cognition.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Studied in animal models and in human clinical research conducted in Russia. PepIndex does not evaluate clinical significance and does not describe administration.
- Functional Connectomic Approach to Studying Selank and Semax Effects — Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections (2020)
Peer-reviewed article indexed in PubMed, published in Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections (2020).
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026)
Peer-reviewed article indexed in PubMed, published in Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026).
- Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats — Bulletin of experimental biology and medicine (2022)
Peer-reviewed article indexed in PubMed, published in Bulletin of experimental biology and medicine (2022).
- Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress — Bulletin of experimental biology and medicine (2019)
Peer-reviewed article indexed in PubMed, published in Bulletin of experimental biology and medicine (2019).
- The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress — Current reviews in clinical and experimental pharmacology (2021)
Peer-reviewed article indexed in PubMed, published in Current reviews in clinical and experimental pharmacology (2021).
- Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats — Bulletin of experimental biology and medicine (2019)
Peer-reviewed article indexed in PubMed, published in Bulletin of experimental biology and medicine (2019).
- Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission — Frontiers in pharmacology (2016)
Peer-reviewed article indexed in PubMed, published in Frontiers in pharmacology (2016).
- GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells — Frontiers in pharmacology (2017)
Peer-reviewed article indexed in PubMed, published in Frontiers in pharmacology (2017).
Indexed studies4 human-evidence of 4
- [Optimization of the treatment of anxiety disorders with selank] — Human — controlled trial, 2015
To compare the efficacy and tolerability of monotherapy with phenazepam to complex treatment with the peptide preparation selank and phenazepam in patients with anxiety disorders. Authors explored the anxiolytic effect and tolerability of monotherapy with phenazepam (30 patients) and complex treatment with selank and phenazepam (40 patients) in anxiety-phobic, hypochondriac and somatoform disorders (ICD-10 items F40.2-9, F41.1-9, F45.0-2). Therapeutic effect was assessed clin…
- [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders] — Human — controlled trial, 2014
Objective. To study the efficacy and tolerability of the new anxyolytic peptide selank in comparison with phenazepam. Material and methods. A comparative study of the anxiolytic effect and tolerability of selank and phenazepam was carried out in 60 patients with phobic-anxiety- and somatoform disorders (F40.2-9, F41.1-9, F45.0-1 by ICD-10) were examined. Results Pronounced anxiolytic and mild nootropic effects of selank were demonstrated. The anxiolytic effect lasted for a we…
- [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia] — Human — controlled trial, 2008
Sixty-two patients with generalized anxiety disorder (GAD) and neurasthenia were studied. The effect of selank (30 patients) was compared to that of medazepam (32 patients). Patient's state was assessed with psychometric scales (Hamilton, Zung, CGI). Enkephalin activity in the blood serum was measured as well. The anxiolytic effects of both drugs were similar but selank had also antiasthenic and psychostimulant effects. The clinical-biological study revealed that patients wit…
- Predictive factors of the presence of pulmonary embolism in patients with interstitial lung disease: Observational study — Human — observational, 2024
In patients with interstitial lung disease (ILD), the risk of pulmonary embolism (PE) is increased; however, distinguishing between PE and ILD exacerbation can be difficult. Therefore, this study investigated the usefulness of the Wells criteria and revised Geneva score and predictive factors for diagnosing PE in ILD patients with worsening respiratory symptoms. We retrospectively collected the data of 65 patients with ILD who underwent computed tomography pulmonary angiograp…
Evidence digest
What the research on Selank actually shows
The indexed literature on Selank includes human clinical or observational records (4 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether Selank is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
3 things the literature does not establish →
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.